Get the Stockscreener App
1.66
6.21%
-0.11
Anebulo Pharmaceuticals Inc stock is traded at $1.66, with a volume of 1,052.
It is down -6.21% in the last 24 hours and up +43.10% over the past month.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
See More
Previous Close:
$1.77
Open:
$1.73
24h Volume:
1,052
Relative Volume:
0.05
Market Cap:
$44.78M
Revenue:
-
Net Income/Loss:
$-7.92M
P/E Ratio:
-5.5333
EPS:
-0.3
Net Cash Flow:
$-7.05M
1W Performance:
-1.19%
1M Performance:
+43.10%
6M Performance:
+13.70%
1Y Performance:
-26.87%
1-Day Range:
$1.66
$1.73
1-Week Range:
$1.57
$2.00
52-Week Range:
$0.8001
$3.08
Anebulo Pharmaceuticals Inc Stock (ANEB) Company Profile
Name
Anebulo Pharmaceuticals Inc
Sector
Industry
Phone
737 203 5270
Address
C/O ANEBULO PHARMACEUTICALS, INC., LAKEWAY
Compare ANEB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANEB
Anebulo Pharmaceuticals Inc
|
1.66 | 44.78M | 0 | -7.92M | -7.05M | -0.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Anebulo Pharmaceuticals Inc Stock (ANEB) Latest News
Benchmark cuts Anebulo stock target to $3, keeps Speculative Buy By Investing.com - Investing.com Canada
Anebulo Pharmaceuticals (NASDAQ:ANEB) Is In A Good Position To Deliver On Growth Plans - simplywall.st
Benchmark cuts Anebulo stock target to $3, keeps Speculative Buy - Investing.com
Anebulo Pharmaceuticals (ANEB) Price Target Lowered by Maxim Gro - GuruFocus
Anebulo Pharmaceuticals (ANEB) Sees Price Target Reduced but Ret - GuruFocus
Anebulo Pharmaceuticals Focuses on Pediatric Cannabis Toxicity Treatment - TipRanks
Anebulo Pharmaceuticals (ANEB) Projected to Post Earnings on Wednesday - Defense World
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates - Business Wire
Head to Head Contrast: OnKure Therapeutics (NASDAQ:OKUR) & Anebulo Pharmaceuticals (NASDAQ:ANEB) - Defense World
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Large Increase in Short Interest - Defense World
Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation - Yahoo
Anebulo Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com India
Anebulo Pharmaceuticals regains Nasdaq compliance - Investing.com Australia
Anebulo Pharmaceuticals expands shares, restructures board - Investing.com Australia
Anebulo Pharmaceuticals expands shares, restructures board By Investing.com - Investing.com South Africa
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Down 12.3% in March - Defense World
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Mangrove Partners IM, LLC Acquires Significant Stake in Anebulo Pharmaceuticals Inc - GuruFocus
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Anebulo Pharmaceuticals Inc Files For Resale Of Up To 15.15 Million Shares By The Selling Stockholders - Marketscreener.com
Benchmark maintains Speculative Buy on Anebulo stock, target at $8 By Investing.com - Investing.com Canada
Anebulo Pharmaceuticals enters lock-up agreement, faces Nasdaq compliance issue By Investing.com - Investing.com South Africa
Anebulo Pharmaceuticals enters lock-up agreement, faces Nasdaq compliance issue - Investing.com
Anebulo Pharmaceuticals files to sell 15.15M shares of common stock for holders - MSN
Anebulo Pharmaceuticals Reports Fiscal Q2 2025 Results - TipRanks
Anebulo Pharmaceuticals Inc Files Prospectus Related To Resale Of 15.2 Million Shares Of Common Stock By Selling Stockholders- SEC Filing - Marketscreener.com
Anebulo Pharmaceuticals Inc. (ANEB) reports earnings - Quartz
Anebulo Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Anebulo Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Anebulo's Cannabis Overdose Treatment Gets FDA Priority Signal as Company Raises $15M - StockTitan
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates - Business Wire
Head to Head Contrast: ProQR Therapeutics (NASDAQ:PRQR) versus Anebulo Pharmaceuticals (NASDAQ:ANEB) - Defense World
Anebulo Pharmaceuticals sets annual meeting for April 4, 2025 By Investing.com - Investing.com Nigeria
Anebulo Pharmaceuticals sets annual meeting for April 4, 2025 - MSN
Anebulo Pharmaceuticals Leads This Trio Of US Penny Stocks - Yahoo Finance
Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Increases By 2,174.1% - Defense World
Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Expands By 2,174.1% - Defense World
3 US Penny Stocks With Market Caps Under $800M - Yahoo Finance
Anebulo Pharmaceuticals sees $9.99m stock acquisition by 22NW fund - Investing.com UK
Anebulo Pharmaceuticals collaborates with FDA to advance selonabant - Yahoo Finance
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise - Business Wire
Anebulo Pharmaceuticals Inc Stock (ANEB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):